Home › PTC Therapeutics Begins Rolling NDA Submission To The FDA For Translarna To Treat Duchenne Muscular Dystrophy
 

Keywords :   


PTC Therapeutics Begins Rolling NDA Submission To The FDA For Translarna To Treat Duchenne Muscular Dystrophy

2014-12-29 01:59:52| drugdiscoveryonline Home Page

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has commenced a rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for Translarna™ for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD)

Tags: treat begins rolling submission

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.11SHODO-X 12 7
28.11 CT 300MG RIGHT() 24
28.11Coleman
28.11CD / 88cm CDS
28.11PSA10 e
28.11YAMAHA
28.11PSA 10 HOLW91055
28.11nima
More »